Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies
May 03, 2018 16:01 ET
|
Sarepta Therapeutics, Inc.
-- Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise -- -- The program is designed, if successful, to offer first-ever corrective treatments for five distinct...
Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments
May 03, 2018 16:01 ET
|
Sarepta Therapeutics, Inc.
-- First quarter 2017 EXONDYS 51® (eteplirsen) total net revenues of $64.6 million -- -- Sarepta signs exclusive partnership and buy-out option with Myonexus Therapeutics; pipeline expands from 16 to...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2018 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Developments on May 3, 2018
April 23, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 30, 2018 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., March 30, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program
March 20, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Plan to Submit a New Drug Application (NDA) for Accelerated Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53
March 12, 2018 07:30 ET
|
Sarepta Therapeutics, Inc.
-- The Company met with the FDA Division of Neurology Products in February to obtain guidance on the regulatory pathway for golodirsen -- -- The Company intends to complete a rolling NDA submission...
Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments
March 01, 2018 16:01 ET
|
Sarepta Therapeutics, Inc.
-- Fourth quarter 2017 EXONDYS 51® (eteplirsen) total net revenues of $57.3 million -- -- Cash and investment balance of $1.1 billion as of December 31, 2017 -- CAMBRIDGE, Mass., March 01, 2018 ...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2018 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics to Present at Two Upcoming Investor Conferences
February 27, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...